Abstract
Purpose:
To describe a case of recurrent, bilateral panuveitis caused by the BRAF proto-oncogene inhibitor vemurafenib.
Methods:
Case report.
Results:
A 25-year-old woman developed bilateral panuveitis and macular edema after initiating treatment with the BRAF enzyme inhibitor vemurafenib for stage IV cutaneous melanoma. The patient was successfully treated with sub-Tenon triamcinolone injections along with cessation of the medication.
Conclusions:
Panuveitis is a potential adverse effect of vemurafenib. Good communication with oncology is necessary, in case the medication needs to be discontinued.
MeSH terms
-
Adult
-
Female
-
Humans
-
Indoles / adverse effects*
-
Macular Edema / chemically induced
-
Macular Edema / drug therapy
-
Melanoma / drug therapy*
-
Melanoma / pathology
-
Melanoma, Cutaneous Malignant
-
Neoplasm Staging
-
Panuveitis / chemically induced*
-
Panuveitis / drug therapy
-
Proto-Oncogene Mas
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Recurrence
-
Skin Neoplasms
-
Sulfonamides / adverse effects*
-
Tenon Capsule / drug effects
-
Triamcinolone Acetonide / therapeutic use
-
Vemurafenib
Substances
-
Indoles
-
MAS1 protein, human
-
Proto-Oncogene Mas
-
Sulfonamides
-
Vemurafenib
-
Proto-Oncogene Proteins B-raf
-
Triamcinolone Acetonide